Liz Jones Hollis

Articles by Liz Jones Hollis

Sanofi's ($SNY) Shantha buyout fails to live up to expectations

Sanofi-Aventis' ($SNY) acquisition of Indian vaccine maker Shantha Biotechnics has failed to live up to analyst forecasts, according to Bloomberg. Sanofi announced in July 2009 that it was paying

New vaccine offers hope in fight against pneumonia, meningtis

University of Leicester and Trinity College Dublin researchers have provided promising data in the fight against pneumonia, meningtis and septicaemia--and the discovery could lead to a new

CMS: Data shows moderate support for Provenge use

All of the available data for Dendreon's Provenge prostate cancer vaccine shows 'moderate' support for its use, according to a government analysis. CMS, which meets with outside advisers next

BiondVax looks to make mark in universal flu vax space

As we reported earlier, developing a universal flu vaccine is of great interest to many firms, with companies like BiondVax Pharmaceuticals and VaxInnate looking to make their marks in the field.

Discovery could show why cancer vaccines have failed

Cambridge researchers believe they have stumbled upon why scientists have struggled in using the immune system to fight tumors. New research has shown that a type of stromal cell found in many

Aaron Diamond team working on HIV vax

Aaron Diamond AIDS Research Center director and chief executive David Ho Da-i recently told a Hong Kong medical conference that his team is working on an HIV vaccine. And if everything goes well, Ho

Study: Support of mandatory HPV vaccine declines after negative news coverage

Laws mandating the HPV vaccine have aroused debate among parents, politicians, and medical and public health experts. And news coverage about such requirements tend to amplify this controversy,

GlobeImmune HCV vax shows promise in trial

GlobeImmune's GI-5005, the company's investigational Tarmogen product, improved sustained virologic response by 12 percent in patients with genotype 1 chronic hepatitis C virus infection who had

Sanofi dengue vax enters PhIII

Sanofi Pasteur's dengue vaccine has entered its first Phase III clinical study in Australia. The study is part of a global Phase III clinical study program aimed at advancing the development of a

Report: Higher income parents increasingly forgoing kids' vaccinations

Vaccination rates for children insured by commercial plans declined roughly four percentage points between 2008 and 2009. And experts fear that if this trend continues, the public's health could be